Cataract surgery is among the most performed surgical procedures worldwide, and outcomes are generally excellent. Yet even after uncomplicated surgery, a small but meaningful subset of patients experiences persistent visual disturbances related to their intraocular lenses (IOLs) that affect quality of life. These phenomena, collectively termed pseudophakic dysphotopsias, represent the leading cause of patient dissatisfaction after cataract surgery. Reported incidence rates reach as high as 49% of patients postoperatively,1 with approximately 19% of patients reporting symptoms on the first day after surgery.2
For the majority of patients, these symptoms diminish over time through a process of neuroadaptation. However, for those who remain symptomatic at 6 months to 1 year after surgery, a practical framework is needed to determine when to observe, how to provide support, and when surgical intervention should be considered.
Background: Types of Dysphotopsia
Pseudophakic dysphotopsias fall into 2 clinically distinct categories that differ in etiology, presentation, and treatment approach.
-
Positive dysphotopsia (PD) refers to unwanted light-based phenomena—including streaks, arcs, halos, and starbursts—typically triggered by external light sources. The pathophysiology of PD is well understood, with good correlation between optical laboratory findings and clinical presentation. IOL edge design, refractive index, and optic design all contribute to PD, with the truncated or square-edge design of modern IOLs identified as the primary source of internal light reflection onto the retinal surface.3 A subset of this category, diffractive optic dysphotopsia, arises from the diffraction rings on presbyopia-correcting IOLs.4
-
Negative dysphotopsia (ND) presents as a dark temporal peripheral arc or shadow. Unlike PD, ND has been reported only with in-the-bag IOLs regardless of material, edge design, or index of refraction, and has not been reported with ciliary-sulcus, anterior-chamber, or scleral suture-fixated IOLs.3 Horizontal IOL orientation has been associated with a reduced incidence of negative dysphotopsia in some trials,5 although the optimal orientation and durability of this effect remain uncertain. Intraocular lens position relative to the anterior capsulotomy is the key factor. Adding to its complexity, ND has a central nervous system component. When the contralateral eye was occluded, ND scotoma was reduced in approximately 80% of cases.3 Patients with ND tend to report greater distress than those with PD, as the perception of a missing portion of the visual field is often more alarming than intermittent light phenomena.7
Neuroadaptation: Timeline and Natural History
The natural history of pseudophakic dysphotopsia is characterized by gradual improvement in most patients.
For ND, the incidence of early postoperative symptoms may be as high as 15% to 20% but decreases to approximately 3% at 1 year, largely because of neuroadaptation.3 Patients with symptoms persisting beyond 3 to 6 months are considered to have chronic dysphotopsia, which warrants a more structured management approach.6
The trajectory for PD differs. Symptoms are typically present from postoperative day 1, and true neuroadaptation to PD is exceedingly rare.6 Early improvement in PD symptoms may reflect capsule fibrosis around the IOL, which gradually stabilizes lens-edge optics—a physical change rather than true neuroadaptation.6 Patients with persistent PD should therefore be counseled earlier that spontaneous resolution is unlikely and intervention may ultimately be required.
For both PD and ND, a period of observation of at least 3 to 6 months is recommended before any surgical intervention is considered.6 During this window, conservative measures and reassurance remain the primary tools.
Conservative Management
Before considering any intervention, exclude competing causes of visual disturbance. Retinal pathology, posterior capsule opacification, residual refractive error, and tear film abnormalities can each independently produce symptoms that mimic dysphotopsia and should be systematically evaluated and treated.3,7
It is also important to distinguish true PD from a Maddox rod effect caused by posterior capsule striae, which can be managed with Nd:YAG capsulotomy.6 However, if IOL exchange is being considered, Nd:YAG capsulotomy should be deferred, as an open capsule significantly increases the complexity and risk of the procedure.6
For ND specifically, reassurance should include explaining that this phenomenon occurs only after anatomically uncomplicated in-the-bag IOL surgery and does not reflect any underlying retinal or optic nerve pathology.6 Patients can be reassured that ND symptoms improve in the vast majority of cases.6 For patients with ND, active observation for at least 3 to 6 months is appropriate, as most symptoms improve with neuroadaptation. During this period, patients should be encouraged to focus on their overall visual improvement rather than the dysphotopsia itself, as excessive attention to the symptom may reinforce its perceived significance.
For PD, pharmacologic miosis with pilocarpine 0.5% or brimonidine 0.15% twice daily may reduce symptoms during the observation period by decreasing pupil size and limiting the amount of peripheral light reaching the IOL edge.6 In contrast, ND symptoms typically worsen with miosis and improve with dilation, a pattern that can also help confirm the diagnosis.7
Surgical Considerations and Options
For most patients, conservative management and reassurance are sufficient, and surgical intervention is not required. When surgical intervention is considered, transparent discussion of risks, benefits, alternatives, and realistic expectations remains critical. The decision to proceed should be based on symptom severity, functional disability, and the patient's tolerance of persistent symptoms rather than on the mere presence of dysphotopsia. Although corrective procedures can be highly successful, complete symptom resolution cannot be guaranteed. Patients who understand these limitations are better positioned to make informed decisions and are more likely to remain satisfied with their overall care regardless of the treatment chosen.
Intraocular lens exchange carries procedural risks, including capsular compromise, zonular dehiscence, endophthalmitis, and cystoid macular edema. These risks are influenced by time elapsed since surgery, the extent of capsular fibrosis, and surgeon experience.4 Patients should also understand that although success rates are favorable, complete resolution of symptoms cannot be guaranteed.
The choice of surgical intervention depends critically on whether the patient has PD, ND, or both, as the 2 conditions require fundamentally different approaches. For persistent PD, the treatment of choice is IOL exchange to a lens with a lower index of refraction. In a retrospective series of 56 eyes from 46 patients, IOL exchange resulted in improvement or resolution of PD symptoms in 85.7% of cases after a single procedure. When the inciting IOL was acrylic, exchange to silicone achieved an 87% success rate and exchange to copolymer achieved 88%, with no statistically significant difference between the two.4 No patients in that series reported worsening symptoms after exchange.4
For ND, the surgical goal is positional, not material, change. In-the-bag IOL exchange alone, even for a lens of different material or edge design, does not relieve ND when the replacement lens remains in the capsular bag.8 What matters is whether the IOL optic overlies the anterior capsulotomy edge. Three surgical strategies achieve this, with varying success rates reported by Masket and colleagues in a series of 61 patients.6
-
Reverse optic capture, in which the IOL haptics remain in the capsular bag while the optic is prolapsed anteriorly through the capsulorhexis, achieved improvement in 96% of cases. It requires an intact capsulorhexis of approximately 4.8 mm to 5.0 mm and a 3-piece IOL. Patients should be counseled that accelerated posterior capsule opacification is likely, and that a refractive shift toward myopia may occur.4,7
-
Bag-to-sulcus IOL exchange, in which the in-the-bag lens is removed and a 3-piece IOL is placed in the ciliary sulcus, achieved improvement in 86% of cases.6
-
Piggyback IOL implantation, in which a secondary sulcus IOL of a different material is placed anterior to the existing in-the-bag lens, achieved improvement in 73% of cases. Iris chafing is a recognized risk and may lead to pigment dispersion and glare.6
For patients with combined PD and ND, bag-to-sulcus exchange or reverse optic capture is the recommended approach.4
Overall, advances in IOL edge and material design have helped reduce the incidence and severity of dysphotopsia. Consequently, surgical intervention remains uncommon. In our experience, the vast majority of patients never require surgery—rather, they improve with reassurance, observation, and close follow-up. Surgical correction should be reserved for patients with truly debilitating symptoms that persist despite an adequate period of observation, in whom competing diagnoses have been excluded, and for whom realistic expectations for intervention have been established.
Practice Considerations
Persistent dysphotopsia presents a unique challenge because patients may remain dissatisfied despite an objectively successful surgery. These patients often have excellent visual acuity, normal ocular examinations, and uncomplicated surgical courses, yet continue to experience symptoms that affect quality of life. In such cases, preserving patient trust becomes as important as managing the optical phenomenon itself.
Effective management begins before surgery. Although it remains impossible to predict which patients will develop dysphotopsia, preoperative counseling is an underutilized but valuable tool. Patients, particularly younger individuals whose higher visual demands and longer life expectancy make dysphotopsia more consequential, should be informed of the possibility of postoperative photic phenomena. Larger photopic and mesopic pupil size have been associated with higher dysphotopsia scores, and dry eye disease and vitreous opacities are independently associated with greater glare symptoms following diffractive multifocal IOL implantation.9 Positive dysphotopsia is linked to high-refractive-index square-edge acrylic optics, flat anterior surfaces, smaller optic diameters, and especially multifocal optics. Setting realistic expectations before surgery can reduce patient distress if symptoms develop and foster a more constructive postoperative course. Effective expectation management is also effective practice management. Standardizing preoperative counseling scripts, scheduling brief reassurance check-ins during the neuroadaptation window, and ensuring that surgeons, technicians, and schedulers deliver consistent messaging all reduce the number of unplanned visits driven by patient anxiety rather than clinical need.
Equally important is the surgeon's response to the patient's concerns. Patients presenting with dysphotopsia after an otherwise uncomplicated surgery are at risk of feeling dismissed. Acknowledging the symptoms, validating the patient's experience, and directly discussing the expected clinical course are therapeutic interventions in themselves.7
Surgeons must recognize that patient satisfaction often depends less on objective surgical success than on how postoperative concerns are addressed. Although cataract surgery is routine and complications may be absent, patients experiencing disturbing visual symptoms frequently compare their outcomes with those of friends or family members and may question whether their surgery was successful. Maintaining trust through empathy, transparency, and ongoing communication is therefore essential.
From a practice-management perspective, unresolved dissatisfaction extends beyond a single clinical encounter. Patients who feel unheard may be less likely to return for future care, proceed with surgery in the fellow eye, or recommend the practice to others. In an era of online reviews and publicly shared experiences, proactive communication and consistent follow-up are important not only for patient care but also for maintaining a practice's reputation.
Surgeons should be honest and transparent about dysphotopsia, provide a clear explanation of the expected course, and outline available management options. Regular follow-up is particularly important for anxious patients, so they do not feel abandoned during the neuroadaptation period. Patients should feel informed, involved, and empowered in decisions regarding observation vs intervention, and they should never feel pressured to proceed with second-eye surgery before their concerns have been adequately addressed.
Conclusion
Ultimately, the successful management of dysphotopsia extends beyond identifying an optical cause or selecting a treatment strategy. It requires setting realistic expectations, validating patient concerns, and maintaining a therapeutic partnership throughout the postoperative course. Although many cases improve with time and neuroadaptation, the surgeon's commitment to communication, reassurance, and shared decision-making often determines whether patients view their cataract surgery as a success.
References
1. Tester R, Pace NL, Samore M, Olson RJ. Dysphotopsia in phakic and pseudophakic patients: incidence and relation to intraocular lens type. J Cataract Refract Surg. 2000;26:810-816. doi:10.1016/s0886-3350(00)00427-2
2. Bournas P, Drazinos S, Kanellas D, Arvanitis M, Vaikoussis E. Dysphotopsia after cataract surgery: comparison of four different intraocular lenses. Ophthalmologica. 2007;221(6):378-383. doi:10.1159/000107496
3. Masket S, Fram NR. Pseudophakic dysphotopsia: review of incidence, cause, and treatment of positive and negative dysphotopsia. Ophthalmology. 2021;128:e195-e205. doi:10.1016/j.ophtha.2020.08.009
4. Masket S, Rupnik Z, Fram NR, Kwong S, McLachlan J. Surgical management of positive dysphotopsia: US perspective. J Cataract Refract Surg. 2020;46(11):1474-1479. doi:10.1097/j.jcrs.0000000000000307
5. Pamulapati SV, Saeed JM, Pompey N, Gomez KD, Vakharia MR. Randomized controlled trial of intraocular lens orientation for dysphotopsia. Am J Ophthalmol. 2022;243:28-33. doi:10.1016/j.ajo.2022.06.018
6. Fram NR. How to manage pseudophakic dysphotopsia. Ophthalmology Management. June 1, 2020. Accessed August 17, 2026. https://ophthalmologymanagement.com/issues/2020/june/how-to-manage-pseudophakic-dysphotopsia/
7. Hu J, Sella R, Afshari NA. Dysphotopsia: a multifaceted optic phenomenon. Curr Opin Ophthalmol. 2018 Jan;29(1):61-68. doi: 10.1097/ICU.0000000000000447
8. Masket S, Fram NR. Pseudophakic negative dysphotopsia: surgical management and new theory of etiology. J Cataract Refract Surg. 2011;37:1199-1207. doi:10.1016/j.jcrs.2011.02.022
9. Tuuminen R, Jeon S. Association of ocular comorbidities on long-term patient-reported outcome measures after multifocal intraocular lens implantation. Am J Ophthalmol. 2026;281:384-394. doi:10.1016/j.ajo.2025.10.001
